Cholestatic hepatitis from prolonged kratom use: A case report

Hepatology

Volumn 61, Issue 3, 2015, Pages 1086-1087

  Dorman, Christina ^a   Wong, Mark ^b   Khan, Aazib ^c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HERBACEOUS AGENT; KRATOM; QUETIAPINE; SERTRALINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CASE REPORT; CAUCASIAN; CHOLESTATIC HEPATITIS; CONFUSION; DRUG USE; DRUG WITHDRAWAL; FEVER; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LABORATORY TEST; LIVER INJURY; MALE; MITRAGYNA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RASH; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT DURATION; ADVERSE EFFECTS; CHEMICALLY INDUCED; INTRAHEPATIC CHOLESTASIS; MIDDLE AGED;

CHOLESTASIS, INTRAHEPATIC; HUMANS; MALE; MIDDLE AGED; MITRAGYNA;

EID: 84923267244     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27612     Document Type: Article

References (4)

1. Prozialeck W, Jivan J, Andurkar S. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 2012;112:792-799.
2. Forrester M. Kratom exposures reported to Texas poison centers. J Addict Dis 2013;32:396-400.
3. Kapp F, Maurer H, Auwärter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol 2011;7:227-231.
4. SNI National. SNI National is voluntarily recalling Kratom XL 4 pack, Maeng Da Kratom 10 pack, Max Kratom 20 pack, and Bali Kratom 40 pack due to undeclared drug ingredients. 2014. Available at: http://www.fda.gov/Safety/Recalls/ucm389350.htm. Accessed August 1, 2014.